Stocklytics Platform
Asset logo for symbol RCKT
Rocket Pharmaceuticals
RCKT43
$23.45arrow_drop_down0.59%-$0.14
Asset logo for symbol RCKT
RCKT43

$23.45

arrow_drop_down0.59%
Key Stats
Open$23.01
Prev. Close$23.35
EPS-2.85
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range22.43
23.60
52 Week Range14.89
32.52
Ratios
Revenue-
EBITDA Margin %-
EPS-2.85
Fundamentals
Gross Profit-
Payout Ratio-
Industry average yield2.86%
Last Dividend pay dateJan 5, 2018
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

RCKTarrow_drop_up1.03%
US Healthcare Sectorarrow_drop_down0.16%
US Marketarrow_drop_up0.90%
check_circle
RCKT / Market
RCKT exceeded the US Market which returned 0.90% over the last twenty four hours.
check_circle
RCKT / Healthcare Sector
RCKT exceeded the US Healthcare sector which returned -0.16% over the last twenty four hours.

Rocket Pharmaceuticals (RCKT) Statistics

Rocket Pharmaceuticals Inc (RCKT) is a biotechnology company specializing in the development of gene therapies for rare and devastating diseases. The company's stock statistics show a strong performance in recent years, with its share price steadily increasing. This positive stock performance can be attributed to the company's promising valuation metrics and fundamentals. Rocket Pharmaceuticals Inc has been able to generate significant revenue per share, demonstrating its ability to monetize its products. Additionally, the company's Enterprise to EBITDA ratio indicates a healthy financial position, further contributing to its positive stock performance. Rocket Pharmaceuticals Inc also boasts a high profit margin, showing its efficiency in generating profits from its operations. As for its Total Debt, the company has managed to keep it at a manageable level, reducing financial risk. Rocket Pharmaceuticals Inc's gross profit has also been consistently high, reflecting its strong revenue generation. Overall, the company's stock performance has outperformed the sector in which it operates, indicating its competitive advantage and market strength.

Leading the charge at Rocket Pharmaceuticals Inc is its CEO, who plays a pivotal role in driving the company's success. The CEO is responsible for overseeing the overall strategic direction of the company and ensuring its growth and profitability. Through their leadership, the CEO guides the development and execution of Rocket Pharmaceuticals Inc's gene therapy programs, ensuring they align with the company's mission and values. With their expertise and experience in the biotechnology industry, the CEO is integral in establishing partnerships and collaborations to further advance the company's research and development efforts. By fostering a culture of innovation and excellence, the CEO motivates and inspires the team at Rocket Pharmaceuticals Inc to strive for breakthrough therapies that can transform the lives of patients suffering from rare diseases. Their vision and commitment to the company's mission make them a driving force in the success of Rocket Pharmaceuticals Inc.

add Rocket Pharmaceuticals  to watchlist

Keep an eye on Rocket Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
How has Rocket Pharmaceuticals (RCKT) stock's performance compared to its sector and the market over the past year?

Over the past year, Rocket Pharmaceuticals (RCKT) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 27.65%, Rocket Pharmaceuticals has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 49.36%, it has fallen short of the market average. This comparison highlights Rocket Pharmaceuticals 's performance relative to both its sector and the overall market over the last year.

help
What is the PE ratio of Rocket Pharmaceuticals (RCKT) stock?

The PE ratio for Rocket Pharmaceuticals (RCKT) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.

help
What is the EPS of Rocket Pharmaceuticals (RCKT) stock?

The Earnings Per Share (EPS) for Rocket Pharmaceuticals (RCKT), calculated on a diluted basis, is -$2.85. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

help
What is the operating margin of Rocket Pharmaceuticals (RCKT) stock?

The operating margin for Rocket Pharmaceuticals (RCKT) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

help
What is the EBITDA of Rocket Pharmaceuticals (RCKT) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Rocket Pharmaceuticals (RCKT) is -$257.16M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

help
How much debt does Rocket Pharmaceuticals (RCKT) have?

Rocket Pharmaceuticals (RCKT) has a total debt of $25.95M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$9.33M.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level